<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755066</url>
  </required_header>
  <id_info>
    <org_study_id>2505</org_study_id>
    <secondary_id>EudraCT 2005-004274-24</secondary_id>
    <nct_id>NCT00755066</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE</brief_title>
  <official_title>The Effect of Intranasal Corticosteroid on the Immune Response Following Nasal Allergen Challenge in Patients Suffering From Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergy Centre Vienna West</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Evaluation of the effect of fluticasone propionate vs placebo applied as nasal spray on the&#xD;
      increase of allergen-specific serum IgE levels following nasal exposure to recombinant&#xD;
      allergens. Nasal sprays will be applied for four weeks starting two weeks before nasal&#xD;
      provocation and serum IgE levels will be followed during eight weeks after nasal provocation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allergen specific IgE levels</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allergen specific IgG 1-4, IgM, IgA levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone propionate 200 µg intranasal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intranasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate</intervention_name>
    <description>200 µg intranasal, 4 weeks, od.</description>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intranasal spray</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female 18-50 years of age&#xD;
&#xD;
          -  moderate to severe allergic rhinitis to grass and/or birch pollen for at least two&#xD;
             seasons according to history&#xD;
&#xD;
          -  sensitization to rPhl p 5 and rBet v 1 as demonstrated by UniCAP within a range from&#xD;
             3.0-80 kUA/l and a positive (wheal diameter &gt;= 3 mm larger than the negative control&#xD;
             and half of the histamine control) SPT with rPhl p 5 and rBet v 1 at 20 µg/ml&#xD;
&#xD;
          -  willingness to comply with the study protocol&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  perennial allergic rhinitis&#xD;
&#xD;
          -  history of asthma necessitating treatment&#xD;
&#xD;
          -  FEV1 &lt;70% of predicted value&#xD;
&#xD;
          -  abnormalities at auscultation of heart or lungs&#xD;
&#xD;
          -  history of anaphylaxis&#xD;
&#xD;
          -  severe atopic dermatitis&#xD;
&#xD;
          -  total serum IgE &gt;2000 kU/l&#xD;
&#xD;
          -  previous or ongoing immunotherapy (subcutaneous or sublingual) to grass or birch&#xD;
             pollen&#xD;
&#xD;
          -  nasal provocation testing during the previous six month&#xD;
&#xD;
          -  known allergy/intolerance to fluticasone propionate or loratadine&#xD;
&#xD;
          -  known allergy/intolerance to cellulose, polysorbate, phenylethyl alcohol, benzalkonium&#xD;
             chloride&#xD;
&#xD;
          -  contraindications for the use of INCS:&#xD;
&#xD;
          -  acute or chronic infections of the upper respiratory tract&#xD;
&#xD;
          -  surgery of the nose during the previous year&#xD;
&#xD;
          -  hypersensitivity to components of the drug&#xD;
&#xD;
          -  contraindications for nasal provocation test&#xD;
&#xD;
          -  acute rhinosinusitis&#xD;
&#xD;
          -  acute allergic reaction of the immediate type at other organs&#xD;
&#xD;
          -  nasal polyposis or significant nasal anatomical deformities&#xD;
&#xD;
          -  vasomotor rhinitis&#xD;
&#xD;
          -  autoimmune disease, chronic or acute infectious disease, malignancy&#xD;
&#xD;
          -  severe psychological disorder&#xD;
&#xD;
          -  treatment with systemic or topical (intranasal, inhaled, external) corticosteroids&#xD;
             from 3 month prior to the study&#xD;
&#xD;
          -  treatment with other immunosuppressant drugs from 6 month prior to the study&#xD;
&#xD;
          -  treatment with antihistamines or disodium cromoglycate from 2 weeks prior to the study&#xD;
&#xD;
          -  treatment with intranasal adrenergic drugs from 3 days prior to the study&#xD;
&#xD;
          -  treatment with systemic adrenergic drugs&#xD;
&#xD;
          -  treatment with psychopharmacological drugs from 2 weeks prior to the study&#xD;
&#xD;
          -  cardiovascular or pulmonary disease&#xD;
&#xD;
          -  contraindication for adrenaline&#xD;
&#xD;
          -  participation in any other clinical trial within the previous 3 month&#xD;
&#xD;
          -  pregnant, lactating or sexually active women with childbearing potential who are not&#xD;
             using a medically accepted birth control method&#xD;
&#xD;
          -  a mental condition rendering the subject unable to understand the nature, scope and&#xD;
             possible consequences of the study, and/or evidence of an uncooperative attitude&#xD;
&#xD;
          -  known alcohol or drug addiction or abuse&#xD;
&#xD;
          -  unlikelihood to be able to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Centre Vienna West</name>
      <address>
        <city>Vienna</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

